Allogeneic hematopoietic stem cell transplant with reduced-intensity conditioning for chronic lymphocytic leukemia in Sweden: does donor T-cell engraftment 3 months after transplant predict survival?
(2012) In Leukemia & Lymphoma 53(9). p.1699-1705- Abstract
- Thirty-eight adult patients with chronic lymphocytic leukemia (CLL) underwent reduced-intensity conditioning (RIC) allogeneic stem cell transplant (allo-SCT) in Sweden between 1999 and 2007. The cumulative incidences of acute graft-versus-host disease (GVHD) grades II-IV and chronic GVHD were 29% and 47%, respectively. Rates of non-relapse mortality, progression-free survival (PFS) and overall survival (OS) were 18%, 47% and 74% at 1 year, and 21%, 25% and 45% at 5 years, respectively. T-cell chimerism after transplant was measured in 31 out of 34 patients (91%) surviving beyond day + 100. Seventeen patients achieved > 90% donor T-cell engraftment at 3 months after allo-SCT and, compared with the 12 patients with <= 90% donor T-cell... (More)
- Thirty-eight adult patients with chronic lymphocytic leukemia (CLL) underwent reduced-intensity conditioning (RIC) allogeneic stem cell transplant (allo-SCT) in Sweden between 1999 and 2007. The cumulative incidences of acute graft-versus-host disease (GVHD) grades II-IV and chronic GVHD were 29% and 47%, respectively. Rates of non-relapse mortality, progression-free survival (PFS) and overall survival (OS) were 18%, 47% and 74% at 1 year, and 21%, 25% and 45% at 5 years, respectively. T-cell chimerism after transplant was measured in 31 out of 34 patients (91%) surviving beyond day + 100. Seventeen patients achieved > 90% donor T-cell engraftment at 3 months after allo-SCT and, compared with the 12 patients with <= 90% donor T-cell engraftment, they showed favorable PFS at 1 year (82% vs. 33%, p = 0.002) and better long-term PFS and OS (p = 0.002 and 0.046, respectively). Donor T-cell engraftment of > 90% at 3 months after RIC allo-SCT for CLL seems to predict favorable short-term and long-term outcome. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/3147742
- author
- organization
- publishing date
- 2012
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Allogeneic stem cell transplant, chronic lymphocytic leukemia, T-cell, donor engraftment
- in
- Leukemia & Lymphoma
- volume
- 53
- issue
- 9
- pages
- 1699 - 1705
- publisher
- Taylor & Francis
- external identifiers
-
- wos:000307301500012
- scopus:84864996370
- pmid:22335529
- ISSN
- 1042-8194
- DOI
- 10.3109/10428194.2012.666661
- language
- English
- LU publication?
- yes
- id
- abcb9dd8-0e09-4089-b0f7-e7fdf9cd4a9a (old id 3147742)
- date added to LUP
- 2016-04-01 13:01:57
- date last changed
- 2024-06-19 07:22:37
@article{abcb9dd8-0e09-4089-b0f7-e7fdf9cd4a9a, abstract = {{Thirty-eight adult patients with chronic lymphocytic leukemia (CLL) underwent reduced-intensity conditioning (RIC) allogeneic stem cell transplant (allo-SCT) in Sweden between 1999 and 2007. The cumulative incidences of acute graft-versus-host disease (GVHD) grades II-IV and chronic GVHD were 29% and 47%, respectively. Rates of non-relapse mortality, progression-free survival (PFS) and overall survival (OS) were 18%, 47% and 74% at 1 year, and 21%, 25% and 45% at 5 years, respectively. T-cell chimerism after transplant was measured in 31 out of 34 patients (91%) surviving beyond day + 100. Seventeen patients achieved > 90% donor T-cell engraftment at 3 months after allo-SCT and, compared with the 12 patients with <= 90% donor T-cell engraftment, they showed favorable PFS at 1 year (82% vs. 33%, p = 0.002) and better long-term PFS and OS (p = 0.002 and 0.046, respectively). Donor T-cell engraftment of > 90% at 3 months after RIC allo-SCT for CLL seems to predict favorable short-term and long-term outcome.}}, author = {{Machaczka, Maciej and Johansson, Jan-Erik and Remberger, Mats and Hallbook, Helene and Malm, Claes and Lazarevic, Vladimir and Wahlin, Anders and Omar, Hamdy and Juliusson, Gunnar and Kimby, Eva and Hagglund, Hans}}, issn = {{1042-8194}}, keywords = {{Allogeneic stem cell transplant; chronic lymphocytic leukemia; T-cell; donor engraftment}}, language = {{eng}}, number = {{9}}, pages = {{1699--1705}}, publisher = {{Taylor & Francis}}, series = {{Leukemia & Lymphoma}}, title = {{Allogeneic hematopoietic stem cell transplant with reduced-intensity conditioning for chronic lymphocytic leukemia in Sweden: does donor T-cell engraftment 3 months after transplant predict survival?}}, url = {{http://dx.doi.org/10.3109/10428194.2012.666661}}, doi = {{10.3109/10428194.2012.666661}}, volume = {{53}}, year = {{2012}}, }